MTPC, Daiichi Sankyo Conduct Largest Ever Copromotion for Tenelia, Aiming for Top Position in Diabetes Market with SGLT-2 Inhibitor

With the launch of the DPP-4 (dipeptidyl peptidase-4) inhibitor Tenelia (teneligliptin) on September 10, Mitsubishi Tanabe Pharma Corporation (MTPC) and Daiichi Sankyo are trying to penetrate into the increasingly competitive diabetes market, emphasizing its profile in comparison with other existing...read more